U.S. Personal Products Stock News

Wondering whether eToro Group's share price still reflects its true worth, or if the recent moves have pushed it away from fair value. Over the short term, the stock has seen an 18.2% return over 7 days and 1.6% over 30 days, while the year to date return sits at a 10.8% decline from the last close of US$31.84. This price action is occurring against a backdrop of ongoing attention on online trading platforms and broader interest in listed fintech businesses, which keeps sentiment in play...

ReposiTrak (TRAK) has put up another steady quarter in Q2 2026, reporting revenue of US$5.9 million and basic EPS of US$0.09, with net income excluding extra items at US$1.6 million as investors weigh these figures against its recent growth track record. The company has seen quarterly revenue move from US$5.5 million in Q2 2025 to US$5.9 million in the latest quarter, while basic EPS over that span has ranged between US$0.08 and US$0.10. This is setting the stage for investors to focus on how...

If you are looking at Union Pacific and wondering whether the current share price still offers value, you are not alone. This article is built to help you think through that question clearly. The stock last closed at US$265.00, with returns of 0.8% over 7 days, 15.5% over 30 days, 14.3% year to date, 9.8% over 1 year, 48.6% over 3 years, and 40.4% over 5 years. This naturally raises questions about what is already priced in and what might still be on the table. Recent news around Union...

Coursera, NYSE:COUR, has announced an agreement to combine with Udemy. The companies plan to create a larger online learning platform with a focus on AI powered experiences. The move signals consolidation in online education and is expected to be closely watched by investors and industry participants. For investors tracking NYSE:COUR, the announcement comes after a challenging period for the share price. Coursera closed at $5.93, with a 3.3% gain over the past week but declines of 5.7% over...

If you are wondering whether Illumina's current share price lines up with its underlying worth, this article will walk you through what the numbers are really saying about value. The stock closed at US$120.09, with returns of 3.2% over the last 7 days, a 15.2% decline over 30 days, a 10.6% decline year to date, a 16.6% gain over 1 year, a 38.7% decline over 3 years and a 73.2% decline over 5 years. The pricing story has therefore been quite mixed across different time frames. Recent news...

MFA Financial (MFA) has put up steady quarterly numbers in FY 2025 so far, with Q3 revenue of US$85 million and EPS of US$0.36, alongside net income of US$37 million. The company has seen revenue move between US$72 million and US$90 million per quarter over the past six reported periods, with EPS ranging from a small loss of US$0.02 to US$0.38. This gives investors a clearer view of how the income line and per share results have tracked through recent conditions. With trailing 12 month net...

Remitly Global (NasdaqGS:RELY) has appointed Sebastian Gunningham as CEO, succeeding co founder Matt Oppenheimer. The leadership change coincides with the announcement of Remitly's first full year of GAAP profitability. The company also reported record quarterly financial results alongside the CEO transition. Remitly focuses on digital cross border remittances, offering migrant workers and their families app based money transfer services. The combination of a new CEO and confirmation of...

Suburban Propane Partners (SPH) caught investor attention after reporting first quarter 2025 earnings, with net income of US$45.78 million compared to US$19.42 million a year earlier, on relatively stable revenue of about US$370 million. See our latest analysis for Suburban Propane Partners. The latest earnings release appears to sit alongside gradually improving sentiment, with a 30 day share price return of 5.52% and a 90 day gain of 8.35%. The 5 year total shareholder return of 96.45%...

Wingstop (WING) just posted its FY 2025 third quarter numbers, reporting revenue of US$175.7 million and basic EPS of US$1.02, while trailing twelve month EPS is US$6.15 on revenue of US$683.0 million. The company’s revenue has moved from US$162.5 million and EPS of US$0.88 in Q3 2024 to US$175.7 million and EPS of US$1.02 in Q3 2025. This sits alongside trailing net income of US$174.3 million, which contributes to the 25.5% net margin reported over the past year and highlights a results...

Analog Devices (ADI) opened its new fiscal year with Q1 2026 results that sit on top of a clear ramp in recent quarters, with revenue moving from US$2,443.2 million in Q4 2024 to US$3,076.1 million in Q4 2025 and basic EPS stepping up from US$0.96 to US$1.60 over the same period. Over the trailing twelve months to Q4 2025, total revenue reached US$11.0 billion and basic EPS came in at US$4.59. This gives investors a fuller sense of earnings power coming into this latest print and sets the...

Clinical and earnings updates shift focus for Roivant Sciences (ROIV) Roivant Sciences (ROIV) shares are in focus after the company reported a key clinical milestone for its pulmonary hypertension program and quarterly results that showed lower sales and a larger net loss compared with last year. See our latest analysis for Roivant Sciences. The clinical milestone and latest earnings are landing against a backdrop of strong momentum, with Roivant Sciences showing a 30 day share price return...

Bausch + Lomb (NYSE:BLCO) has put out its latest FY 2025 numbers with Q3 revenue of US$1.3b and a basic EPS loss of US$0.08, as investors weigh how far the business has come toward closing the profitability gap. The company has seen quarterly revenue move from US$1.1b in Q1 2025 to US$1.3b in Q3, while basic EPS losses over that stretch ranged from US$0.60 in Q1 to US$0.18 in Q2 and US$0.08 in Q3. This sets up the current update as a check-in on how quickly margins can repair from here. See...

RB Global (RBA) has wrapped up FY 2025 with fourth quarter revenue of US$1.2 billion and basic EPS of US$0.53, alongside net income excluding extra items of US$99.1 million. This sets a clear marker for how the year finished. Across recent periods, the company has seen quarterly revenue range from US$981.8 million in Q3 2024 to US$1.2 billion in Q4 2025, while basic EPS moved between US$0.36 and US$0.56 over that span. This gives investors a concrete view of how the top and bottom lines have...

Recent moves in Weis Markets stock Weis Markets (WMK) has caught investor attention after a steady run, with the share price at $72.70 and total return figures that differ sharply between the past month, past 3 months, and recent years. See our latest analysis for Weis Markets. At a share price of $72.70, Weis Markets has seen short term momentum, with a 30 day share price return of 5.38% and a 90 day share price return of 10.86%. The 1 year total shareholder return of 3.45% contrasts with a...

If you are wondering whether GE HealthCare Technologies is fairly priced today, this article walks through what the current share price might be implying about its underlying value. The stock last closed at US$82.95, with returns of 4.7% over the past week, 1.5% over the past month, a small 0.2% gain year to date, and a 10.2% decline over the past year. These moves may have some investors reassessing the balance between upside potential and risk. Recent attention on GE HealthCare has focused...

In February 2026, TriNet Group reported fourth-quarter 2025 revenue of US$1,248 million with a net loss of US$1 million, and full-year 2025 revenue of US$5,010 million with net income of US$155 million, alongside new 2026 guidance and an update on its long-running share repurchase program. The company’s 2026 outlook, which points to lower total revenue of US$4,750 million to US$4,900 million and reduced diluted earnings per share of US$2.15 to US$3.05, raises fresh questions about how its...

TransMedics Group received full FDA approval for its Next-Generation OCS ENHANCE Heart trial Investigational Device Exemption. The trial is designed to assess the company’s Organ Care System Heart technology for prolonged heart perfusion versus current storage methods. This FDA decision marks a material development for NasdaqGM:TMDX and its organ transplant platform. TransMedics Group, trading on NasdaqGM:TMDX, now has a fresh regulatory green light that adds to its profile in the heart...

If you are wondering whether Krystal Biotech's share price reflects its true worth, this article will walk through how the current market price compares with a range of valuation checks. The stock last closed at US$283.29, with returns of 3.9% over 7 days, 14.7% year to date, and 60.8% over the past year. This performance has put it firmly on many investors' radar. Recent interest in Krystal Biotech has been shaped by ongoing attention to its gene therapy pipeline and regulatory milestones...

Similarweb (SMWB) has wrapped up FY 2025 with Q4 revenue of US$72.8 million and a basic EPS loss of US$0.09, alongside net income excluding extra items of a US$7.5 million loss. The company has seen revenue move from US$65.6 million in Q4 2024 to US$72.8 million in Q4 2025, while quarterly basic EPS shifted from a US$0.07 loss to a US$0.09 loss over the same period. This sets up a story focused on how quickly margins can tighten or ease from here. See our full analysis for Similarweb. With...

Moody's (MCO) has just posted third quarter FY 2025 revenue of US$2.0b and basic EPS of US$3.61, with trailing twelve month revenue at US$7.5b and EPS at US$12.48 framing the latest print within a larger earnings run rate. The company has seen quarterly revenue move from US$1.82b in Q2 2024 to US$1.90b in Q2 2025 and then US$2.01b in Q3 2025, while basic EPS moved from US$3.03 to US$3.22 and then US$3.61 over the same quarters, giving investors a clear view of how the income statement is...

Goosehead Insurance (GSHD) closed FY 2025 with fourth quarter revenue of US$105.3 million and basic EPS of US$0.50, alongside trailing twelve month revenue of US$365.3 million and EPS of US$1.11 that frame the latest print in a wider context of reported earnings. Over the past six quarters, revenue has moved from US$77.8 million in Q3 2024 to US$105.3 million in Q4 2025, while quarterly EPS has ranged from US$0.09 in Q1 2025 to US$0.60 in Q4 2024. This gives investors a clearer view of how...

Fiverr International (FVRR) just posted its FY 2025 numbers with Q3 revenue of US$107.9 million and basic EPS of US$0.15, set against trailing twelve month revenue of US$427.4 million and EPS of US$0.62 that reflect earnings growth of 121.2% over the past year. The company has seen quarterly revenue move from US$94.7 million in Q2 2024 to a range of roughly US$107 million to US$108.6 million across the first three quarters of 2025. Over the same 2025 periods, basic EPS shifted from US$0.09 in...

Starboard Value has launched an activist campaign targeting Tripadvisor's board, seeking to replace a majority of directors. The investor is urging Tripadvisor to consider options to maximize shareholder value, including a possible sale of the company. Starboard has criticized Tripadvisor's strategic direction, use of Generative AI, and past decisions it views as unfavorable to shareholders. For anyone tracking NasdaqGS:TRIP, this campaign comes after a challenging stretch for the stock...

IDEAYA Biosciences (IDYA) has wrapped up FY 2025 with Q4 revenue of US$10.9 million, a basic EPS loss of US$0.94, and net income excluding extra items at a loss of US$83.3 million. Trailing twelve month figures show revenue of US$218.7 million and a basic EPS loss of US$1.28. Over recent quarters, the company’s revenue moved from US$7.0 million in Q4 2024 to US$207.8 million in Q3 2025 before landing at US$10.9 million in Q4 2025. Basic EPS ranged from a loss of US$1.49 in Q4 2024 to a profit...